BUD13

Across TCGA pan-cancer cohorts, BUD13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BUD13 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BUD13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BUD13 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where BUD13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.699	0.886	.001	23	view →
UCEC	DFS	Quartile	All	0.766	0.960	.023	6	view →
LUAD	OS	Median	II,III,IV	0.891	0.455	.035	2	view →
LSCC	OS	Quartile	II,III,IV	0.931	0.650	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BUD13–PDAC (DFS)

Open the PDAC breakdown →